Founded in 2017, Hims & Hers Health (HIMS +0.74%) is a telemedicine company that sells prescription and over-the-counter drugs online directly to consumers. Originally, the company was founded as Hims Inc. and focused on providing wellness solutions to male patients dealing with sensitive health concerns. However, the company quickly expanded to cover both men's and women's health.
Today, Hims & Hers Health provides customers in all 50 states and Washington D.C. access to consultations, primary care services, and other virtual care services from licensed healthcare professionals 100% online.
In addition to an extensive provider network, users can pay to have both prescription and nonprescription products on the platform delivered to their home for free, though there's often a subscription fee to access prescriptions that are fulfilled online through its partner network of licensed pharmacies. Many of its nonprescription products are also available for sale at retail locations across the country.
NYSE: HIMS
Key Data Points
Read on to learn more about this company and how to invest in the stock.
How to buy Hims & Hers Health stock
Because Hims & Hers Health stock is publicly traded, you can easily buy whole or fractional shares through your brokerage account. Here's a step-by-step look at how that would work.
- Open your brokerage account: Log in to your brokerage account where you handle your investments.
- Search for the stock: Enter the ticker or company name into the search bar to bring up the stock's trading page.
- Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this stock.
- Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you're willing to pay.
- Submit your order: Confirm the details and submit your buy order.
- Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.
Stock
Should I invest in Hims & Hers Health?
There are numerous reasons investors might want to scoop up at least a few shares. Hims & Hers Health expanded its reach in the anti-obesity drug marketplace in 2024 when it began offering access to injectable Glucagon-like peptide-1 (GLP-1) weight loss drugs. This is a space that analysts estimate could reach a valuation of more than $100 billion before the end of the decade. And Hims & Hers Health's expansion into the weight loss market is just one slice of the pie.
Its focus on key areas of the virtual healthcare space means the business faces a broad total addressable market where there is definitely room for multiple successful players. For example, management estimates that demand for quality telehealth solutions for sexual health affects 80 million individuals in the U.S. Mental healthcare services, another key specialty market and area of focus for Hims & Hers, represents approximately 100 million lives.
Additionally, Hims & Hers offers a wide selection of generic and personalized treatment options that keep users coming back. Subscribers grew 31% year over year in the second quarter of 2025. The company believes it will deliver $2.3 to $2.4 billion in revenue in 2025. Hims & Hers is also targeting to deliver up to $335 million in earnings before interest, taxes, depreciation, and amortization (EBITDA) in 2025.
Is Hims & Hers Health profitable?
Yes, Hims & Hers Health stock is profitable. The company reported its first profitable quarter at the end of 2023, bringing in $1.2 million in net income. In the second quarter of 2025, it delivered a net income of $42.5 million.
Does Hims & Hers Health pay a dividend?
Hims & Hers Health stock does not pay a dividend and has not announced its intention to start one in the future. Given that the company is investing heavily in its growth at this point in time and is a relatively new business, a dividend seems unlikely anytime soon.
Will Hims & Hers Health stock split?
Hims & Hers Health stock went public in January 2021 via a $1.6 billion special purpose acquisition company (SPAC). The company has not split its stock.
Usually, a company will split its stock when shares become too high or too low, or outpace those of similar companies in the industry, making an investment less accessible to wide groups of investors. Shares of Hims & Hers Health trade around $53 at the time of this article, so a stock split seems highly unlikely at any point in the near future.
Related investing topics
The bottom line on Hims & Hers Health
Hims & Hers is growing steadily. Revenue and subscribers are consistently on the upswing. Profitability is improving. Its diverse potential audience could prime the company to snag shares in multiple lucrative segments of the telemedicine market.
The telehealth market is a competitive space, but consumers tend to spend on healthcare in a wide range of economic cycles, just as they do consumer staples. That lends a certain level of resilience to companies operating in this space.
Hims & Hers Health is a growth-oriented stock, so it might not be an ideal choice for value-oriented or dividend-seeking investors. However, for investors with an ample buy-and-hold horizon who want a stake in a profitable telehealth business with a steady growth runway ahead, Hims & Hers Health stock may be a solid addition to a long-term investment portfolio.
FAQ
About the Author
